Theralase begins small animal preclinical trials for destruction of cancer cells

Nov. 11, 2010
Theralase Technologies Inc. has begun the preclinical trial phase of its cancer research project, evaluating its patented photodynamic compounds (PDCs) in a small animal in-vivo model.

Theralase Technologies Inc. (Toronto, ON, Canada) has begun the preclinical trial phase of its cancer research project, evaluating its patented photodynamic compounds (PDCs) in a small animal in-vivo model.

Lothar Lilge, Ph.D., the principal investigator of the PDCs and a researcher at the world-renowned Ontario Cancer Institute located at Princess Margaret Hospital, University Health Network (UHN) will evaluate the toxicity of the patented PDCs on small animals by choosing an escalating dose analysis. Once completed, Dr. Lilge plans to demonstrate efficacy of the PDCs in the destruction of tumors in a small animal model.

Theralase first announced commencing small animal trials in June 2010. Testing can now proceed, following receipt of approvals on its Animal Utilization Protocol by the UHN Ethics Review Committee.

"These small animal preclinical trials represent the next strategic step forward in our cancer therapy research program," says Theralase President and CEO, Roger Dumoulin-White. "Now that approval has been granted, hands-on evaluation of the PDCs in a small animal model is able to commence full-steam ahead. Successful completion of this milestone will lay the groundwork for exploring the use of these PDCs in the destruction of cancers in larger animals, including horses, cats, dogs and eventually humans."

"Determination of the maximum tolerated dose is critical to providing us with safe PDC dosage levels that we can use to set recommended dosing guidelines to evaluate the efficacy of the PDCs in eradicating tumors in small animals while sparing normal tissue," states Dr. Lilge. "Successfully destroying cancer in at least two animal models, coupled with the completion of an OECD guideline toxicology analysis of the PDCs, will be mandatory in setting the stage for future Phase 1 human clinical trials. We are currently investigating toxicity of four lead compounds in the safe and effective destruction of cancer cells in-vivo. Due to the ability of these PDCs to work in low oxygen environments, these PDCs will be ideally suited in the destruction of solid-core tumors, such as cancers of the breast, prostate, brain and lung."

Source: Theralase Technologies

-----

Posted by Lee Mather

Follow us on Twitter

Subscribe now to BioOptics World magazine; it's free!

Sponsored Recommendations

Melles Griot® XPLAN™ CCG Lens Series

March 19, 2024
IDEX Health & Science sets a new standard with our Melles Griot® XPLAN™ CCG Lens Series fluorescence microscope imaging systems. Access superior-quality optics with off-the-shelf...

Spatial Biology

March 19, 2024
Spatial Biology refers to the field that integrates spatial information into biological research, allowing for the study of biological systems in their native spatial context....

Fluorescent Protein Optical Imaging Considerations

March 19, 2024
What factors should you consider when your incorporate fluorescent proteins in an optical imaging application? Learn more.

Custom-Engineered Optical Solutions for Your Application

March 19, 2024
We combine advanced optical design and manufacturing technology, with decades of experience in critical applications, to take you from first designs to ongoing marketplace success...

Voice your opinion!

To join the conversation, and become an exclusive member of Laser Focus World, create an account today!